<DOC>
	<DOCNO>NCT00809848</DOCNO>
	<brief_summary>The study evaluate safety efficacy AGN-210669 ophthalmic solution comparison AGN-210669 vehicle bimatoprost ophthalmic solution dose once-daily morning , subject ocular hypertension primary open-angle glaucoma . Subjects follow 2 week .</brief_summary>
	<brief_title>Safety Efficacy AGN 210669 Ophthalmic Solution Patients With Ocular Hypertension Primary Open-Angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension primary openangle glaucoma Females nonchildbearing potential Subject require IOPlowering therapy eye IOP ≥ 22 mm Hg ≤ 34 mm Hg Has visual acuity score 20/100 good eye Uncontrolled systemic disease Active ocular disease Alteration exist chronic systemic medication Known allergy sensitivity study medication Ophthalmic corticosteroid Visual field loss opinion investigator functionally significant History ocular laser , intraocular surgery , refractive surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>